{"id":"arthemeter-lumefantrine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL38827","moleculeType":"Small molecule","molecularWeight":"528.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemether, a semi-synthetic artemisinin derivative, rapidly kills malaria parasites by generating reactive oxygen species that damage parasite proteins and membranes. Lumefantrine, a biguanide-like compound, inhibits parasite heme polymerization and disrupts mitochondrial function. Together, they provide rapid parasite clearance and extended post-treatment suppression.","oneSentence":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:30.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by other Plasmodium species susceptible to artemether-lumefantrine"}]},"trialDetails":[{"nctId":"NCT04222088","phase":"","title":"TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014","status":"COMPLETED","sponsor":"Research Institute for Tropical Medicine, Philippines","startDate":"2013-05-01","conditions":"Malaria, Falciparum Malaria, Vivax Malaria","enrollment":159},{"nctId":"NCT00495508","phase":"PHASE4","title":"Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy","status":"COMPLETED","sponsor":"Epicentre","startDate":"2006-10","conditions":"Malaria","enrollment":300},{"nctId":"NCT01054248","phase":"PHASE3","title":"Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-02-16","conditions":"Malaria","enrollment":511},{"nctId":"NCT00541385","phase":"PHASE3","title":"Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients","status":"COMPLETED","sponsor":"Medicines for Malaria Venture","startDate":"2007-10","conditions":"Malaria","enrollment":535},{"nctId":"NCT05070520","phase":"PHASE4","title":"Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the Agadez, Gaya and Tessaoua Sentinel Sites","status":"COMPLETED","sponsor":"Programme National de Lutte contre le Paludisme, Niger","startDate":"2020-09-01","conditions":"MALARIA","enrollment":259},{"nctId":"NCT02974348","phase":"PHASE3","title":"Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa","status":"COMPLETED","sponsor":"University of Bamenda","startDate":"2013-01","conditions":"Drug Resistant Malaria Due to Plasmodium Falciparum","enrollment":300},{"nctId":"NCT02151578","phase":"PHASE4","title":"Home Management of Malaria and Pneumonia","status":"COMPLETED","sponsor":"World Health Organization","startDate":"2009-01","conditions":"Malaria, Pneumonia","enrollment":11500},{"nctId":"NCT01843764","phase":"","title":"Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections","status":"COMPLETED","sponsor":"Anders Björkman","startDate":"2009-06","conditions":"Plasmodium Falciparum Malaria","enrollment":53},{"nctId":"NCT01445938","phase":"PHASE2","title":"Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria","status":"TERMINATED","sponsor":"Sanofi","startDate":"2011-10","conditions":"Malaria","enrollment":20},{"nctId":"NCT01567423","phase":"NA","title":"Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria","status":"COMPLETED","sponsor":"Epicentre","startDate":"2008-04","conditions":"Malaria, Falciparum","enrollment":301},{"nctId":"NCT00386763","phase":"PHASE3","title":"Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Malaria, Falciparum","enrollment":890}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Coartem","Cofantrine®"],"phase":"phase_3","status":"active","brandName":"Arthemeter-lumefantrine","genericName":"Arthemeter-lumefantrine","companyName":"Research Institute for Tropical Medicine, Philippines","companyId":"research-institute-for-tropical-medicine-philippines","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artemether and lumefantrine work synergistically to kill malaria parasites by disrupting their hemoglobin metabolism and causing oxidative damage. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by other Plasmodium species susceptible to artemether-lumefantrine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}